‘Immunoswitch’ particles may be key to more-effective cancer immunotherapy

Scientists at Johns Hopkins have created a nanoparticle that carries two different antibodies capable of simultaneously switching off cancer cells’ defensive properties while switching on a robust anticancer immune response in mice. Experiments with the tiny, double-duty ‘immunoswitch’ found it able to dramatically slow the growth of mouse melanoma and colon cancer and even eradicate tumors in test animals, the researchers report.